Conversations: Fireside Video Chats
The “Conversations” video series will feature virtual fireside chats with neuroscience experts who will discuss advances in the research and treatment of Alzheimer’s disease, dementia with Lewy bodies (DLB), and other age-related neurodegenerative conditions.
Please note, our podcast series does not constitute the practice of medical advice, diagnosis or treatment. Always talk to your health care provider for diagnosis and treatment, including your specific medical needs. If you have or suspect that you have a medical problem or condition, please contact a qualified health care professional immediately.
Episode 9: Executing Clinical Research in Dementia with Lewy Bodies (DLB)
| Featuring: | |
| Anthony Caggiano, M.D., Ph.D. (moderator) Cognition Therapeutics | Chief Medical Officer |
| James E. Galvin, MD, MPH. University of Miami | Director of the Comprehensive Center for Brain Health, Miller School of Medicine |
| Lawrence S. Honig, MD, PhD, FAAN Columbia University | Professor of Neurology, Irving Medical Center |
| David Shprecher, D.O. Banner Sun Health Research Institute | Movement Disorder Director, Banner Sun Health Clinical Associate Professor, University of Arizona |
| Index: | |
| 0:00 | Introduction |
| 0:45 | Comparing Alzheimer’s disease and DLB |
| 5:02 | SHIMMER Design and Outcomes |
| 10:22 | Metrics for Success in a Signal-finding Study |
share this video
Episode 8: Protecting the Synapse from Amyloid Toxicity in Alzheimer’s Disease
| Featuring: | |
| Anthony Caggiano, M.D., Ph.D. (moderator) Cognition Therapeutics |
Chief Medical Officer |
| Mary Hamby, Ph.D. (moderator) Cognition Therapeutics |
Vice President of Research |
| Everard (Jort) Vijverberg, MD, PhD Alzheimer Center at Amsterdam University Medical Center |
Neurologist and CNS Trial Specialist |
| Tara Spires Jones, DPhil University of Edinburgh |
Personal Chair of Neurodegeneration and Deputy Director of the Centre for Discovery Brain Sciences |
| Index: | |
| 0:00 | Introduction |
| 3:49 | Findings from SEQUEL |
| 6:45 | Clinical observations of CT1812 engagement |
| 9:08 | Proteomic evidence of CT1812 engagement |
| 11:52 | CT1812’s ongoing Phase 2 study |
share this video
Episode 7: Quantitative EEG – Effects of CT1812 on Measures of Synaptic Function in Alzheimer’s Disease
| Featuring: | |
| Anthony Caggiano, M.D., Ph.D. (moderator) Cognition Therapeutics |
Chief Medical Officer |
| Willem de Haan, M.D., Ph.D. Alzheimer Center at Amsterdam University Medical Center |
Neurologist and Senior Researcher |
| Philip Scheltens, M.D. EQT Life Sciences |
Partner and Head of Dementia Fund Former Director of the Alzheimer Center at Amsterdam University Medical Center |
| Index: | |
| 0:00 | Introduction |
| 0:44 | Rationale for the SEQUEL Study Design |
| 2:10 | EEG in neurodegenerative diseases |
| 4:33 | Findings from SEQUEL |
| 9:52 | Key Takeaways |
share this video